On the fly News and insights, exclusive to thefly.com

NKTR

Nektar

$27.95

0.55 (2.01%)

05:43
01/15/20
01/15
05:43
01/15/20
05:43

Nektar withdraws oxycodegol application after panel vote, shares down 14%

Shares of Nektar Therapeutics are trading lower after the company announced that it will withdraw its new drug application for oxycodegol and make no further investment into the program following yesterday's FDA panel vote. Nektar estimates the move will brings cost savings of between $75M to $125M in 2020. The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 27-0 yesterday not to recommend approval of oxycodegol. Nektar shares are down 14%, or $3.96, to $24.00 in premarket trading.

  • 13

    Feb

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.